How Sensitive Is a Prostate-Specific Antigen Measurements? How Sensitive Does It Need to Be?

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 3, 2004, Pages 341-343

  Bock, Jay L ^a   Klee, George G ^b  

^a STONY BROOK UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CATHETER ABLATION; HUMAN; IMMUNOASSAY; MEASUREMENT; MEDICAL SOCIETY; PROGNOSIS; PROSTATE ABLATION THERAPY; PROSTATE CANCER; REVIEW; SENSITIVITY ANALYSIS; TUMOR RECURRENCE;

HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 1542314270     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. Klee GG, Preissner CM, Oesterling JE. Development of a highly sensitive immunochemiluminometric assay for prostate-specific antigen. Urology. 1994;44: 76-82.
2. Witherspoon LR, Lapeyrolerie T. Sensitive prostate specific antigen measurements identify men with long disease-free intervals and differentiate aggressive from indolent cancer recurrences within 2 years after radical prostatectomy. J Urol. 1997;157:1322-1328.
3. Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol. 1999;161:1206-1211.
4. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591-1597.
5. Slovin S. Biochemical relapse in prostate cancer: is PSA promoting stress and anxiety? Medscape Hematot Oncol ejournal. 2002;5(4). Available at: www.medscape.com/viewarticle/440367. Accessed October 1, 2002.
6. Critz FA. A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol. 2002; 167:1310-1313.
7. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol. 2001;165:1146-1151.